Recent Updates — PPCB

The Nasdaq Stock Market notified Propanc Biopharma, Inc. that its common stock is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. Due to a prior reverse stock split within the last year, the company is ineligible for the standard 180-day cure period and faces delisting on November 2, 2026. Propanc intends to appeal this determination by October 30, 2026, asserting it has already cured the deficiency. The filing notes that a potential delisting could negatively impact stock liquidity, investor interest, and access to public capital markets. Propanc Biopharma is a clinical-stage biotechnology company focused on developing oncology treatments.

Effective July 8, 2026, Annie Van Broekhoven retired and resigned from the Board of Directors. The Board appointed Carlo Campiciano, a qualified accountant and former CFO and Company Secretary of MedAdvisor Limited, to fill the vacancy. Propanc Biopharma, Inc. is a biopharmaceutical company.